Citadel Advisors’s Vicarious Surgical RBOT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-117
Closed -$6.41K 14966
2023
Q2
$6.41K Buy
117
+44
+60% +$2.8K ﹤0.01% 13426
2023
Q1
$4.99K Buy
+73
New +$5.68K ﹤0.01% 13906
2022
Q3
Sell
-910
Closed -$80K 13434
2022
Q2
$80K Sell
910
-890
-49% -$109K ﹤0.01% 11594
2022
Q1
$273K Buy
1,800
+600
+50% +$112K ﹤0.01% 10798
2021
Q4
$382K Buy
1,200
+590
+97% +$208K ﹤0.01% 10343
2021
Q3
$274K Buy
+610
New +$193K ﹤0.01% 11255

Other funds holding RBOT

Citadel Advisors's RBOT Position: Q3 2023 in Review

Citadel Advisors sold out of Vicarious Surgical (RBOT) in Q3 2023, closing a stake of 35 shares — an estimated $1.91K sold.

Citadel Advisors first reported a position in RBOT in Q4 2020 and held it in 8 quarters. The position peaked at $13M in Q2 2021. 83 funds tracked by Wall St. Rank hold RBOT as of Q3 2023.

  • Citadel Advisors reported no remaining Vicarious Surgical position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 35 Vicarious Surgical shares in Q3 2023, an estimated $1.91K.
  • Citadel Advisors first reported a position in Vicarious Surgical in Q4 2020 and held it in 8 quarters.
  • Citadel Advisors's Vicarious Surgical position peaked at $13M in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Vicarious Surgical as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.